My Scanner Told Me To Sell
My Scanner Told Me to Sell. I Almost Listened. Here’s Why That Would Have Been the Worst Trade of the Year.
Two weeks ago I built a rule into the Catalyst Scanner that said: if your position drops 15% from your cost basis with no negative news, sell 25% to reduce the pain and free up capital.
Last week, that rule triggered. One of my active positions — an Orphan Blockbuster with Breakthrough Therapy Designation, $200 million in cash, a confirmed regulatory filing next month, a 42% earnings beat, and unanimous Buy ratings from every analyst who covers it — dropped 24% from my cost basis over four weeks.
The rule said sell. I almost did.
Then my own framework asked me a question I couldn’t answer: if the thesis is the same, why would you sell?
I couldn’t answer it because there is no answer. Selling a binary catalyst position because the stock price went down — not because the drug failed, not because the FDA pushed back, not because the company ran out of money — is paying for emotional comfort with real money. The rule was wrong. I deleted it and replaced it with something better.
This is the story of the most important lesson the scanner has learned so far.
What the drawdown relief rule actually was
The idea seemed reasonable when I wrote it. Biotech stocks are volatile. Watching a position go from -5% to -10% to -15% is psychologically brutal, especially when you’re holding for a binary event that’s still weeks away. The rule was designed as a pressure valve — sell a quarter of the position, reduce the pain, keep 75% for the catalyst.
It sounded like discipline. It was actually fear wearing a suit.
Here’s what selling 25% at the -15% threshold would have done in practice. I entered 2,500 shares at $4.36 average. At -15%, that’s $3.706 per share. Selling 625 shares at $3.706 locks in a realized loss of $409. Those 625 shares, if held through a successful regulatory filing and approval, would be worth $6,250 or more at conservative analyst targets. The “pain management” would have cost me $5,841 in potential gains.
Five thousand eight hundred dollars to feel better for a few weeks. That’s not a trade. That’s a therapy bill.
What actually changed during the 24% decline
I went through it item by item. This is the exercise that killed the rule.
The drug’s Phase 3 data hadn’t changed. The mechanism was still the only frataxin replacement therapy in development. The FDA had granted Breakthrough Therapy Designation. The agency had aligned on a surrogate endpoint for accelerated approval. A cross-species publication had just strengthened the scientific case. The company had just confirmed the regulatory filing was on track for the following month. Earnings had beaten estimates by 42%. Cash was $200 million with runway into 2027. Every single analyst who covered the stock rated it a Buy.
What had changed was the stock price. It went down.
That’s it. The stock went down and the rule said to sell. But a stock going down is not a thesis. A stock going down while the drug still works, the FDA is still engaged, and the company still has $200 million in cash means the market is temporarily mispricing the asset. And temporary mispricing is literally the entire reason this trading strategy exists. If the market correctly priced every biotech with an upcoming FDA decision, there would be no 2-5x moves to capture. The opportunity IS the mispricing.
Selling into the mispricing because it got more mispriced is the opposite of what the framework was designed to do.
The rule that replaced it
The drawdown relief rule is gone. In its place is something I call the Four Pillars Test.
When a position drops 15% or more from cost basis, the price decline is treated as a prompt — a signal to check whether something fundamental has changed. Not a signal to sell. The test evaluates four pillars, and only the test result determines the action.
The first pillar is the drug. Has the clinical thesis changed? Did the data disappoint? Did a safety signal emerge? Was the mechanism challenged by new science? If the reason you bought the stock is no longer supported by the evidence, that’s a real sell signal.
The second pillar is the pathway. Has the regulatory path been damaged? Was the filing delayed or withdrawn? Did the FDA issue a refusal to file? Did the company announce it expects a rejection? Did a manufacturer fail an inspection? If you can no longer reach the binary event, the trade is broken.
The third pillar is the company. Has the financial survival changed? Did a going concern warning appear? Did toxic dilution activate? Did cash run out? If the company can’t survive to the decision date, the drug’s quality doesn’t matter.
The fourth pillar is the competitive moat. Has a competitor emerged that fundamentally changes the long-term value of your drug? Not an incremental improvement from a me-too — a paradigm shift. A gene therapy that could cure what your drug treats chronically. A new mechanism that obsoletes yours. This doesn’t usually change the approval probability, but it changes what the approval is worth.
All four pillars intact means hold. Regardless of price. Regardless of how much it hurts. The catalyst is the only thing that matters, and nothing about the catalyst has changed.
One pillar broken means reassess. Determine severity. A minor crack — an analyst cutting a price target, a non-critical delay — warrants heightened monitoring, not selling. A major break — clinical data failure, cash cliff, paradigm-shifting competitor with strong data — warrants trimming or exiting.
Two or more pillars broken is a strong sell signal. If three or four are broken, the thesis is dead.
What this means for how I trade
The Four Pillars Test fundamentally changes the relationship between price and action in a binary catalyst framework. Under the old rule, price decline triggered selling. Under the new rule, price decline triggers analysis. The analysis — not the price — determines what happens next.
This matters because the entire strategy is built on buying stocks the market has mispriced ahead of a defined binary event. If I sell every time the mispricing gets more extreme, I’m systematically exiting my best positions at their worst prices. The stocks that drop the most on no news are often the ones with the most explosive pops on approval, because the starting point is so depressed.
The rule also means I’ll sit through more pain. A position that’s down 24% with all four pillars intact stays in the portfolio. That’s uncomfortable. But comfort isn’t the objective. The objective is being positioned correctly when the FDA makes its decision. Everything between now and then is noise.
The broader lesson
Every rule in a trading framework exists to prevent a specific mistake. The drawdown relief rule was built to prevent panic selling — the impulse to dump 100% on a bad day. That impulse is real and dangerous, and having a structured response is better than having no plan at all.
But the rule solved the wrong problem. The problem isn’t “I’m down 15% and I might panic sell everything.” The problem is “I’m down 15% and I don’t know whether the thesis has changed.” The Four Pillars Test solves the right problem. It gives you a structured way to evaluate whether the decline means something or means nothing, and then act accordingly.
The scanner is now on version 3.2. It started two weeks ago with a rigid price filter that would have killed my best trade, a drawdown rule that would have sold my best position at its lowest price, and no framework for competitive threats. Every one of those gaps was exposed by running real money through the system. Every one was fixed.
The framework at any single point in time isn’t the edge. The feedback loop that makes it better after every mistake is the edge.
Not financial advice. I hold positions in stocks discussed and will always disclose them. Biotech trading involves substantial risk of total capital loss. The Catalyst Scanner documents my personal research process — nothing here is a recommendation to buy or sell any security. Do your own due diligence. Past results don’t predict future performance.